ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-11-10: Form 8-K; Period of report 2011-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-11-10: Form 8-K; Period of report 2011-11-08; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2011-08-09: Form 8-K; Period of report 2011-08-09; Description 8.01 Other Events; Details 8.01.
- 2011-08-04: Form 8-K; Period of report 2011-08-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-11-10 | 8-K | 2011-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2011, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2011. | t71920_8k.htm |
| 2011-11-10 | 8-K | 2011-11-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | t71912_8k.htm |
| 2011-08-09 | 8-K | 2011-08-09 | 8.01 Other Events | 8.01 On August 9, 2011, Kyowa Hakko Kirin Co., Ltd., ("Kyowa Hakko Kirin") the licensee of ArQule, Inc. (“the Registrant”) for the exclusive rights to the development and sales of tivantinib (ARQ 197) in Japan and certain other countries in Asia (China, Korea, and Taiwan) announced dosing of the first patient in its Phase 3 trial of tivantinib in combination with erlotinib in NSCLC patients in Asia. | t71296_8k.htm |
| 2011-08-04 | 8-K | 2011-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2011, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2011. | t71258_8k.htm |
| 2011-06-06 | 8-K | 2011-06-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As discussed below, the stockholders of ArQule, Inc. (the “Registrant”) approved an amendment to each of the Registrant’s Amended and Restated 1994 Equity Incentive Plan (the “Equity Plan”) and Amended and Restated 1996 Director Stock Option Plan (the “Director Plan”). | a11-14323_18k.htm |
| 2011-05-05 | 8-K | 2011-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2011, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter ended March 31, 2011. | a11-10936_28k.htm |
| 2011-04-28 | 8-K | 2011-04-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On April 27, 2011, Susan L. Kelley, M.D. was appointed to the Board of Directors of ArQule, Inc. (the “Registrant”). | a11-10936_18k.htm |
| 2011-03-01 | 8-K | 2011-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2011, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the year ended December 31, 2010. | a11-6742_28k.htm |
| 2011-02-28 | 8-K | 2011-02-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 23, 2011, Nancy Simonian, M.D., notified ArQule, Inc. of her intent to resign from the Company’s Board of Directors, and she has tendered her resignation effective as of March 31, 2011. | a11-6742_18k.htm |
| 2011-02-14 | 8-K | 2011-02-10 | 8.01 Other Events | 8.01 On February 10, 2011, ArQule, Inc. (the “Registrant”) received a $25 million payment from Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) in accordance with the terms of their license, co-development and co-commercialization agreement regarding the Registrant’s c-MET inhibitor, ARQ 197. | a11-5878_18k.htm |
| 2011-01-25 | 8-K | 2011-01-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 —Entry into a Material Definitive Agreement. | a11-3541_48k.htm |
| 2011-01-24 | 8-K | 2011-01-19 | 8.01 Other Events | 8.01 On January 19, 2011, we announced a public offering of shares of our common stock. | a11-3541_38k.htm |
| 2011-01-12 | 8-K | 2011-01-12 | 8.01 Other Events | 8.01 On January 12, 2011, ArQule, Inc. (the “Registrant”) and Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) announced the dosing of the first patient in a Phase 3 clinical trial of ARQ 197 in patients with non-small cell lung cancer. | a11-3541_18k.htm |